Celanese Corporation (NYSE: CE), a global technology and specialty materials company, today announced the launch of VitalDose™, an ethylene vinyl acetate (EVA) polymer-based excipient that facilitates drug makers’ efforts to develop and commercialize controlled-release pharmaceutical solutions.
VitalDose excipients are based on EVA polymers and offer a wide degree of flexibility in the design of transdermal, subcutaneous implant and mucosal insert dosage forms. VitalDose offers customizable release properties and the potential for new delivery routes to be used in the development of pharmaceutical product line extensions and new concepts.
“By applying Celanese’s VitalDose EVA excipient technology, we are helping our customers retain an edge in a competitive marketplace filled with complex challenges,” said Mark Murray, general manager of Celanese’s EVA Performance Polymers business. “With competition, particularly from generics, on the rise in the pharmaceutical industry, developing innovative dosage forms is now key to retaining a competitive edge in the industry. Developing new routes of administration for existing products, or enhancing the bioavailability of newly developed yet poorly soluble drugs, is an important option that pharmaceutical companies consider as a strategy to maintain the success of their product franchises,” said Murray.
“Celanese is investing in new and innovative resources to grow with the evolving pharmaceutical industry and is maximizing the value of that investment by building on its exceptional excipient technology with product development support and regulatory expertise to meet its customers’ specialized needs,” said Jon Mortimer, chief technology officer, Celanese Office of Strategic Growth. “VitalDose offers a wide degree of flexibility in the design of controlled release dosage solutions and is another example of how Celanese is committed to helping companies realize innovative growth opportunities through advanced product development.”
Source: http://www.celanese.com/